UNRESECTABLE SOLID NEOPLASM

This early-phase study is testing the safety of combining a new cancer vaccine with an existing immunotherapy drug (pembrolizumab) in patients with advanced solid tumors that have spread and stopped responding to standard treatments. The vaccine is designed to train the immune sy…

This study is testing a new oral drug called TRC102 (methoxyamine) to see if it can make standard chemotherapy drugs more effective against advanced solid tumors and mesothelioma. It aims to find the safest dose and see if the combination can shrink tumors in patients whose cance…

This study tested a two-drug combination (veliparib and topotecan) for people with advanced solid tumors or ovarian cancer that has come back after initial treatment. The first phase aimed to find the safest and most effective dose. The second phase focused on seeing if the combi…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This study tested whether the immunotherapy drug pembrolizumab could help control the growth of rare, advanced cancers that have spread or cannot be removed by surgery. It involved 157 patients with specific rare tumor types who had already tried standard treatments. The goal was…

This early-stage trial is testing the safety and best dose of a three-drug combination (vemurafenib, cetuximab, and irinotecan) for patients with advanced solid tumors that have spread and carry a specific BRAF gene mutation. The goal is to see if combining these drugs—two that b…

This study aims to learn if two specific markers found in tumor tissue can help doctors predict which patients with advanced solid cancers will benefit most from immunotherapy. Sixteen patients with specific genetic mutations in their tumors will receive the immunotherapy drug ni…